Table 2.

Published novel tumor antigen targets in CAR T therapy for GBM.

Study	Target	Conclusions
Jin et al. (64)	CXCR1-or CXCR2	CXCR1 or CXCR2 modified CAR T cells were capable of tumor regression in the GBM preclinical model.
Tang et al. (61)	B7-H3	B7-H3 is overexpressed in GBM patients and can be a therapeutic target.
Yang et al. (65)	NKG2D-BBz	NKG2D CAR-T cells targeted glioblastoma cells and cancer stem cells in an NKG2D-dependent manner.
Wallstabe et al. (66)	alphavbeta3	Alphavbeta3 can enhance CAR reactivity.
Yi et al. (53)	EphA2	EphA2-CAR T cells therapy has been shown to be effective in a preclinical model.
Pellegatta et al. (54)	CSPG4	The expression level of CSPG4 in GBM was high and the heterogeneity was not obvious.
Ge et al. (67)	CD70	CD70 is associated with tumor progression.
Zhu et al. (68)	CD57	CD57 was significantly upregulated in activated human T cells.
Wang et al. (63)	Chlorotoxin	Chlorotoxin-CAR T therapy mediated potent anti-tumor activity in the orthotopic xenograft GBM models.